Answers are grounded in this paper and cite their sources.
Different molecular mechanisms are responsible for primary and secondary imatinib resistance in GISTs. These findings have implications for future approaches to the growing problem of imatinib resistance in patients with advanced GISTs.
No takes yet. Share an insight, caveat, or question.
Heinrich et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: